Surgical messages from NADIM II

Dr. Ricard Ramos
Hospital Clinic Barcelona

Surgical messages from CheckMate 816

Dr. Patrick Forde
St. James's Hospital, Dublin (Ireland)

Perioperative lymph node management in chemo-immune era

Dr. Carlos Gálvez
Hospital General Univ. Dr. Balmis, Alicante

Long-term results of a real life SECT study: segmentectomy vs. lobectomy for c-stage IA lung cancer

Dr. Iker López
Hospital Univ. de Donostia

Discussion

AI in Real-World Data: A new horizon

Dr. Angela Prelaj
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)

Radiomics in lung cancer applied to diagnosis and prediction

Dr. María Jesús Ledesma-Carbayo
Universidad Politécnica de Madrid

AI in digital pathology and multiplex Immunohistochemistry (IHC)

Dr. Sebastian Michels
Cologne University Hospital (Germany)

Analyzing mutagenic events in never smokers lung cancer

Dr. Marcos Diaz-Gay
CNIO, Centro Nacional de Investigaciones Oncológicas, Madrid

Discussion

State of art. Neoadjuvant, advuvant and periadjuvant treatments

Dr. Ramón Palmero
ICO, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona

Value of adjuvant therapy after neoadjuvant therapy

Dr. Enric Carcereny
ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona

Predictive factors for pCR in neoadjuvant setting

Dr. Tina Cascone
MD Anderson Cancer Center, University of Texas (USA)

Improving neoadjuvant strategies

Dr. Mariano Provencio
Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

Discussion

SLCG studies: Early stages NSCLC

Dr. Alejandro Olivares
Hospital Univ. de Salamanca

SLCG studies: Advances stages NSCLC

Dr. Laia Vilà
Hospital Parc Taulí, Barcelona

SLCG studies: Other thoracic tumors and pharmacogenomics studies

Dr. Carlos Aguado
Hospital Clínico San Carlos, Madrid

Long-term survivors in metastatic lung cancer consensus

Dr. Ana Laura Ortega
Hospital Univ. de Jaén

Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC). 2nd SLCG consensus

Dr. Natividad Martínez
Hospital General Univ. Dr. Balmis, Alicante

SLCG consensus: Multidisciplinary approach of sexual dysfunction in patients with lung cancer

Dr. Vanessa Ospina
Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

Induction treatment previously to RT/CT

Dr. Virginia Calvo
Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

Feasibility concomitant immunotherapy and radiotherapy

Dr. Reyes Bernabé
Hospital Univ. Virgen del Rocio, Sevilla

Is there a role for SBRT?

Dr. Javier Luna
Hospital Univ. Fundación Jiménez Díaz, Madrid

Treatment strategies for locoregional disease with oncogenic driver

Dr. Patricia Iranzo
Hospital Univ. Vall d'Hebron, Barcelona

Discussion

Pitfalls of liquid biopsy

Dr. Atocha Romero
Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

Assessment of MRD

Dr. Margarita Majem
Hospital de la Santa Creu i Sant Pau, Barcelona

Monitoring response in oncogenic drivers

Dr. Manuel Cobo
Hospital Regional Univ. de Málaga

New developments in liquid biopsy

Dr. Valeria Denninghoff
GENYO - Centro de Genómica e Investigación Oncológica, Granada

Discussion

Treatment decisions in unfrequent mutations

Dr. Rafael López
Hospital Clínico Univ. de Valladolid

Debate: Pros and Cons combination EGFR treatments - Pros

Dr. Bartomeu Massutí
Hospital General Univ. Dr. Balmis, Alicante

Debate: Pros and Cons combination EGFR treatments - Cons

Dr. José Luis González Larriba
Hospital Clínico San Carlos, Madrid